Dasiglucagon for (CHI)
Congenital hyperinsulinism (CHI) is a rare disease affecting mainly newborns and toddlers. It is caused by a defect in pancreatic .-cells, resulting in insulin overproduction. This leads to persistently and often severely low blood sugar levels (hypoglycemia).
The most severely affected children need to have their pancreas surgically removed within a few months of birth in order to prevent hypoglycemia. This invariably results in the development of type 1 diabetes.
Current treatment options are insufficient: Fewer than one-third of newborns and two-thirds of older children respond to approved medical therapy.
CHI develops in one out of 50,000 (or fewer) children. This corresponds to 180-300 children diagnosed in the U.S. and Europe every year.
Dasiglucagon is a glucagon analog invented by Zealand. It is stable in aqueous formulation, suitable for pump use and therefore for treatment of CHI. Glucagon is the physiological counterregulator of insulin, causing a rise in blood glucose.
In 2017, the U.S. FDA and the European Commission both granted orphan drug designation to dasiglucagon for the treatment of CHI.